Compare General Motors Company (GM) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Spyre Therapeutics Inc. Common Stock — how do they compare? General Motors Company trades at $83.05 (market cap $73.71B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: General Motors Company is far larger — about 9.8× Spyre Therapeutics Inc. Common Stock's market cap, and General Motors Company pays a 0.86% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Motors Company for 83 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| GM | SYRE | |
|---|---|---|
Market Cap | $73.71B | $7.52B |
Volume | 6,224,747 | 1,441,031 |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $108.92 |
52-Week Low | $57.34 | $22.18 |
Typical Hold Time | 83 Days | 0 Days |
Enterprise Value | $176.68B | $6.52B |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $83.05, up 0.83% with a bullish technical signal. The stock shows strong earnings momentum, beating estimates for three consecutive quarters, though Q3 2026 results are pending. Valuation metrics appear reasonable with P/S of 0.42 and P/B of 1.19, while profitability remains modest with 1.05% net margin. Recent news highlights competitive pressures as Toyota narrows the U.S. sales gap and Q3 vehicle sales declined 5.5%.
GM faces near-term headwinds from declining sales and margin pressure, but analyst consensus remains bullish with a $102.33 price target representing 23% upside. The company benefits from regulatory savings and EV partnerships, though execution risks and market share erosion require monitoring. Cash flow stability and dividend payments provide shareholder support amid industry transition challenges.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
